Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Latent prostatic cancer in a consecutive autopsy series.

Literature DB >> 6154966

Latent prostatic cancer in a consecutive autopsy series.

Abstract

In a consecutive series of autopsies, 223 prostates were removed. Latent prostatic cancer (LPC) was found in 50 cases (22%). All the tumours were adenocarcinomas. The frequency increased with age. No conclusive evidence was found of a relationship between prostatic hyperplasia and LPC. The extent of the tumour seemed to have greater prognostic significance than the degree of differentiation.

Entities: Disease

Mesh：

Year: 1980 PMID： 6154966 DOI： 10.3109/00365598009181186

Source DB: PubMed Journal: Scand J Urol Nephrol ISSN： 0036-5599

Keyword Cloud
Cited

19 in total

1. What is the clinically relevant endpoint for cancer prevention trials?

Authors: Maurie Markman
Journal: Curr Oncol Rep Date: 2004-09 Impact factor: 5.075

Review 2. Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

Authors: E A Amin; M Amin
Journal: Pharmacoeconomics Date: 1992-05 Impact factor: 4.981

Review 3. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.

Authors: Jaquelyn L Jahn; Edward L Giovannucci; Meir J Stampfer
Journal: Int J Cancer Date: 2015-01-08 Impact factor: 7.396

4. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Authors: Jeannette M Schenk; Alan R Kristal; Kathryn B Arnold; Catherine M Tangen; Marian L Neuhouser; Daniel W Lin; Emily White; Ian M Thompson
Journal: Am J Epidemiol Date: 2011-05-03 Impact factor: 4.897

Latent prostatic cancer in a consecutive autopsy series.

1. What is the clinically relevant endpoint for cancer prevention trials?

Review 2. Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

Review 3. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.

4. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

5. The overdiagnosis nightmare: a time for caution.

6. Expression of metalloproteinase genes in human prostate cancer.

7. Does educational printed material manage to change compliance with prostate cancer screening?

8. Molecular imaging and fusion targeted biopsy of the prostate.

9. The value of prognostic factors in prostatic cancer.

10. Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma.